{
    "symbol": "ALBO",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-08 20:35:29",
    "content": " This puts the company in the strong place with total Bylvay patients increasing a strong third quarter sales, solid cash position, two successful Phase 3 studies in PFIC and Alagille syndrome and another ongoing Phase 3 in biliary atresia now fully enrolled, continue to be on a steady pace to drive our aspiration of making Bylvay a billion dollar drug in the second half of the decade, key for us to take Bylvay from a PFIC medicine to a leading pediatric cholestatic liver disease drug."
}